SAN FRANCISCO, April 9 /CNW/ -- Burrill & Company, a San Francisco based
global leader in the life sciences with principal activities in Venture
Capital, Private Equity, Merchant Banking and Media, is pleased to announce
the following staff promotions:
Tiba Aynechi to Director, Merchant Banking
Garrett Vygantas, Director, Venture Capital
Neel Patel to Senior Associate, Merchant Banking
Tiba Aynechi joined Burrill Merchant Banking in 2006 following an
internship in the Venture Group. Previously, Tiba was a postdoctoral fellow at
the University of California, San Francisco, developing computational models
for drug discovery. She received her Ph.D. from the Graduate Group in
Biophysics at the University of California, San Francisco.
Garrett Vygantas - Before joining Burrill in 2006, Garrett was with
Genentech's Market Planning Group where he focused on the commercialization
and launch of Lucentis for the treatment of wet age-related macular
degeneration. Dr. Vygantas completed his Transitional Residency at the
University of Pennsylvania and holds M.D. and MBA degrees from Georgetown
University. He is a co-founder and interim CEO of NewBridge Pharmaceuticals
and serves on its Board of Directors. He is a Board Observer of Nora
Therapeutics, Proventys, Ikano Therapeutics, ProteoGenix, and NanoVasc.
Neel Patel has broad advisory experience across life sciences coupled
with functional experience in post-merger integration, turnaround management,
operations and strategic planning. Neel was a management consultant with A.T.
Kearney where he focused on strategy and operations consulting. He also worked
in business development at Roche Diagnostics. He has an MBA from the
University of Chicago Graduate School of Business.
"Our Merchant Banking and Venture Capital Practices continue to perform
very well despite the difficult economic climate that we are currently facing.
The promotions are reflective of the excellent contributions that these three
individuals have made," said, G. Steven Burrill, CEO, Burrill & Company.
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader
in life sciences with activities in Venture Capital, Private Equity, Merchant
Banking and Media. The Burrill family of venture capital funds has over $950
million under management and its merchant banking business is one of the
industry leaders in life sciences transactions. Burrill is also the creator,
sponsor and facilitator of leading industry conferences worldwide and
publisher of a range of bio-intelligence reports including the Burrill Report
(www.burrillreport.com), which tracks the progress of the global biotechnology
industry; the Burrill Report Weekly Brief, and annual "State of the Industry"
report the latest of which is Biotech 2009-Life Sciences: Navigating the Sea
Change, the 23rd report on the industry. This book contains analysis and
perspectives on the performance of the industry in 2008 and projections for
2009 and beyond (www.burrillandco.com/Biotech2009)
For further information:
For further information: Peter Winter, Editorial Director of Burrill &
Company, +1-415-591-5474, email@example.com Web Site: